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Abstract
Hepatitis C infection (HCV) is a major cause of chronic hepatitis and cirrhosis world-
wide. Interferon-based regimen has been the sole therapy to eradicate HCV infection for 
decades. However, this interferon and ribavirin combination is associated with several 
serious adverse events and the sustained virologic response rate was suboptimal. The 
recent discovery of oral direct-acting antiviral agents (DAAs) heralded a revolution in 
the treatment of chronic HCV. This breakthrough in HCV resulted in high rates of HCV 
eradication with sustained virologic response rates ranging between 90 and 100% across 
different genotypes. New therapies were administered orally for 12 or 24 months and this 
resulted in better compliance and few adverse events. DAAs are categorized into four 
major groups namely: NS5B nucleotide inhibitors, NS5B nonnucleoside inhibitors, NS5A 
replication complex inhibitors, and NS3/4A protease inhibitors (PI). Several interferon-
free regimens have been approved and adequately assessed and several new regimens 
with high potencies, less cross-resistance, and better safety profile are in the process of 
approval. Thus, the era of HCV eradication and cure has begun.
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1. Introduction
Hepatitis C virus (HCV) is a major cause of liver cirrhosis, end-stage liver disease, and liver 
transplantation throughout the world [1]. Approximately 170–200 million people equating to 
3% of the world’s population are infected with HCV [2]. The prevalence of HCV varies in dif-
ferent geographic regions. The prevalence of HCV infection is greater in Africa and Asia, with 
infection rates exceeding 5% [3–5]. Egypt has the highest prevalence of hepatitis C in the world, 
with 15% of the population affected [6–8]. In the USA, nearly 2% of the population is infected 
[9, 10]. In Europe, the prevalence ranges from 0.1% in northern European countries and 1% in 
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countries on the Mediterranean [10, 11]. The immigration crisis may increase HCV prevalence 
in Europe given that immigrants originate from countries with high rates of HCV [12].
2. Natural history and outcome of HCV infection
Acute HCV infection is mostly asymptomatic and rarely recognized clinically. Spontaneous 
viral clearance (SVC) occurs in approximately 25% of patients [13, 14]. The striking feature 
of HCV infection is its tendency to persist and evolve to chronic hepatitis. In some patients, 
chronic HCV progresses to liver cirrhosis and hepatocellular carcinoma (HCC) [14, 15].
The outcome of HCV infection depends largely on several host, viral and environmental fac-
tors. During an early stage, HCV infection triggers viral-associated molecular pattern (PAMP) 
receptors resulting in induction of an antiviral state through several pathways such as limiting 
cellular, modifying and degrading viral RNA, altering cellular vesicle trafficking and probably 
other not yet discovered antiviral mechanisms [15–17]. Clearance of HCV is associated with the 
development of robust and multispecific CD4+ and CD8+T-cell responses in blood and liver that 
can be maintained for years after recovery from acute disease [18–20]. In contrast, individuals 
who progress to chronic infection fail to mount such a response or may have inadequate pro-
duction of the cytokines essential to control viral replication. Incomplete control of viral repli-
cation by CD8+ T cells in the absence of sufficient memory CD4+T cells leads to viral persistence 
and emergence of CTL escape mutants [21–24].
Acute resolving hepatitis has been shown to be associated with HCV homogeneity, whereas 
progressing hepatitis correlated with genetic diversity, presumably reflecting greater immune 
pressure during acute spontaneous clearance [25]. Polymorphisms of genes involved in innate 
immunity as well as those in genes encoding cytokines and other immunologic mediators 
may explain spontaneous recovery from acute HCV and influence the strength and nature of 
immune defense. Genes encoding the inhibitory NK cell receptor KIR2DL3 and its human leu-
kocyte antigen C group 1 (HLA-C1) ligand influenced spontaneous resolution of HCV infec-
tion suggesting that inhibitory NK cell interactions are critical for antiviral immunity [26, 27].
To date, there are no reliable methods to predict who will resolve acute HCV spontaneously 
and who will develop chronic HCV. Similarly, no reliable indicators exist for distinguishing 
chronic hepatitis C patients who may develop cirrhosis or HCC. Thus, early effective treat-
ment of patients with HCV is necessary for prevention of progression of liver disease to cir-
rhosis, hepatocellular carcinoma. In the absence of a vaccine against HCV, efficient treatment 
is important for prevention of transmission along with adoption of infection control measures.
3. Evolution of HCV therapy
The ultimate goal of hepatitis C treatment is to reduce the occurrence of end-stage liver dis-
ease and its complications including decompensated cirrhosis, liver transplantation, and 
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HCC. Treatment success is assessed by sustained virologic response (SVR), defined undetect-
able HCV RNA in blood several months after completing a course of treatment [28].
For two decades, the standard of care (SOC) for hepatitis C infection was interferon based. 
IFNα has potent antiviral activity due to its ability to induce IFN-stimulated genes (ISGs) 
that encode proteins which inhibit various stages of viral replication [29]. Type I IFNs bind 
a unique ubiquitous heterodimeric receptor consisting of interferon-alpha receptor 1/2 
(IFNAR1/IFNAR2), resulting in the activation of signaling pathways and induction of a large 
number of IFN-stimulated genes (ISGs). ISG-encoded proteins mediate the antiviral and 
other effects of interferons [29]. IFNAR1 and IFNAR2 are associated with the Janus-activated 
kinases (JAKs) tyrosine kinase 2 (TYK2) and JAK1, respectively. Binding of type I IFNs to 
their heterodimeric receptors leads to activation of JAKs, which results in tyrosine phos-
phorylation of signal transducer and activator of transcription 2 (STAT2) and STAT1; STAT1/
STAT2 migrates into the nucleus and associates with the IFN regulatory factor 9 (IRF9) to form 
the STAT1-STAT2-IRF9 complex. This complex then binds IFN-stimulated response elements 
(ISREs) inside DNA to initiate the transcription of hundreds of different ISGs [30, 31]. IFN 
regulatory genes (IRGs) facilitate both clearance of virus from infected cells and protection of 
neighboring uninfected cells from incoming viral progeny. The antiviral-associated protein 
kinase R (PKR) plays an important role in restricting HCV 1a replication through regulating 
the NF-κB pathway [32, 33].
Initially, chronic hepatitis C was treated by conventional interferon (IFN) monotherapy 
which yielded very poor response rates. Addition of the guano sine analog, ribavirin, to 
conventional interferon was associated with slight improvement in sustained virologic 
response (SVR) although the improvement was far from satisfactory particularly in HCV 
genotypes 1 and 4. Pegylation of the interferon molecule resulted in modification of the 
pharmacokinetic profile of IFN-α-2. Both PEG-IFN-α-2a and PEG-IFN-α-2b have slower 
absorption, more reduced distribution and lower elimination rate than the nonpegylated 
IFN-α. The maintained concentrations of PEG-IFNα allowed longer periods of viral inhi-
bition with once a week dosing. Pegylated interferon and ribavirin therapy resulted in 
improved sustained virologic response (SVR), defined as undetectable HCV RNA 24 weeks 
after completion of treatment. With pegylated interferon alpha-2 and ribavirin (RBV) com-
bination, response rates in genotypes 2 and 3 range between 70 and 80%. However, SVR 
rates in chronic HCV genotypes 1 and 4 infection are suboptimal. Adverse events are com-
mon with interferon-based regimen and include fatigue, flu-like symptoms, anxiety, skin 
rash, and gastrointestinal symptoms such as nausea and diarrhea. Hemolytic anemia is 
frequent due to the use of ribavirin. Some patients treated with PEG-IFN and RBV may 
develop cardiac arrhythmias or severe neuropsychiatric adverse events depression and 
suicidal tendency. The various adverse effects, the long duration of therapy and the need 
to inject interferon reduce compliance and treatment adherence. These factors have driven 
the urgent need to develop new treatments that are safer and more effective (Figure 1). The 
discovery of direct-acting antiviral agents (DAAs) heralded the dawn of a new era of HCV 
cure which was a dream.
Advances in Treatment of Hepatitis C
http://dx.doi.org/10.5772/66719
15
4. Direct-acting antiviral agents (DAAs)
Direct-acting antiviral agents (DAAs) represent a revolution in HCV drug discovery. DAAs 
were developed to improve the SVR rates, reduce adverse events, and improve adherence 
to therapy among HCV patients. DAAs were initially introduced as add-ons to the previous 
standard of care (SOC) consisting of pegylated interferon alpha plus ribavirin (PR). Recently, a 
breakthrough in HCV therapy has been achieved with the introduction of interferon-free all-oral 
DAAs, with SVR rates now in excess of 90% after 12 weeks of therapy for genotype 1 patients.
DAAs target specific steps within the HCV life cycle and disrupt viral replication in an attempt 
to terminate that cycle before its completion (Figure 2) [34]. The first step in the life cycle of 
the virus is cell attachment and entry of HCV RNA through hepatocyte surface receptors. 
The HCV RNA is then translated to one polyprotein of 3010 amino acids that is subsequently 
cleaved by protease. It is then processed into four structural proteins (namely Core, E1, E2, 
and P7) as well as the nonstructural proteins (NS2-3 and NS3-4A proteases, NS3 helicase, and 
NS5B RdRp). All of these enzymes are essential for the replication of the virus and are poten-
tial drug discovery targets [35–37].
4.1. Goals of HCV and endpoints of treatment with DAAs
The goal of therapy is to eradicate HCV infection to prevent hepatic cirrhosis, decompen-
sation of cirrhosis, HCC, and severe extrahepatic manifestations. The endpoint of therapy 
is undetectable HCV RNA in blood by a sensitive assay (with the lower limit of detection 
<15 IU/ml) 12 weeks (SVR-12) and/or 24 weeks (SVR-24) after the completion of treatment. 
Undetectable HCV core antigen (HCV c Ag) 12 or 24 weeks after the completion of therapy 
can be an alternative to HCVRNA testing to assess the SVR12 or the SVR24, respectively 
[38]. In patients with advanced fibrosis and cirrhosis, HCV eradication reduces the rate of 
Figure 1. Evolution of HCV therapy.
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decompensation and will reduce, albeit not abolish the risk of HCC. In these patients sur-
veillance for HCC should be continued.
4.2. Classes of DAAs
There are four classes of DAAs, which are defined by their mechanism of action and therapeu-
tic target. DAAs include NS5B nucleotide inhibitors, NS5B nonnucleoside inhibitors, NS5A 
replication complex inhibitors, and NS3/4A protease inhibitors (PI) (Figure 3).
Figure 2. Hepatitis C life cycle and the targets of direct-acting antiviral agents.
Figure 3. Resistance patterns in different direct-acting antiviral agents (DAAs).
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4.2.1. NS3/4A protease inhibitors (PIs)
PIs block the activity NS3/4A serine protease, an enzyme which inhibits TRIF-mediated Toll-
like receptor signaling and Cardif-mediated retinoic acid–inducible gene 1 (RIG-1) signaling 
resulting in impaired induction of interferons and blocking viral elimination [39, 40]. PIs have 
been grouped according to their resistance profile into first- and second-generation agents 
and into separate waves according to dosing, safety, and tolerability characteristics.
4.2.1.1. First-generation PIs
Telaprevir and boceprevir were the first direct-acting antivirals for treatment of HCV and 
represented the first generation of PIs. Telaprevir or boceprevir was used in combination with 
peginterferon and ribavirin for the treatment of genotype 1 [40, 41]. Although telaprevir or 
boceprevir regimen enhanced SVR rates; the clinical efficacy of the triple regimen was lim-
ited by narrow genotype specificity, low barrier to resistance, and drug-drug interactions. 
This regimen also increased adverse events such as rash and moderate to severe anemia to 
an extent that might require the reduction of the RBV dose. Patient adherence and tolerabil-
ity to triple therapy with BOC or TPV is a challenging issue as the two DAAs should be 
given three times daily with food. Triple therapy was not very effective in previous PEG-IFN/
RBV dual therapy, no responders. From an economic perspective, the triple therapy dramati-
cally increased the costs of HCV treatment which are originally prohibitive. Thus, the clinical 
importance of these agents diminished substantially with the discovery of subsequent-gener-
ation protease inhibitors.
4.2.1.2. Second-wave, first-generation protease inhibitors
The second wave of PIs for HCV includes agents such as simeprevir, asunaprevir, danoprevir, 
faldaprevir, and vaniprevir [42, 43]. Simeprevir (Olysio) is a NS3/4A HCV PI. Simeprevir is a 
macrocyclic compound that noncovalently binds to and inhibits the NS3/4A HCV protease, 
a protein that is responsible for cleaving and processing the HCV-encoded polyprotein, a 
critical step in HCV viral life cycle [42, 43]. Simeprevir shows enhanced binding affinity and 
specificity to NS3/4A when compared with the first-generation PIs, TPV, and BOC.
The safety and efficacy of SIM/PEG-IFN/RBV combination was investigated in treatment-
naïve patients with HCV genotype 1 infection (PILLAR trial) [44]. Enrolled patients received 
different SIM doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a 
and ribavirin (RBV). According to response-guided therapy (RGT) criteria, 79.2–86.1% of 
SMV-treated patients completed treatment by week 24; 85.2–95.6% of these subsequently 
achieved SVR. The safety profile of triple therapy with SIM was found to be comparable to 
that of PEG-IFN/RBV combination therapy [44]. In the QUEST 1 and QUEST 2 studies [45, 
46], conducted on treatment-naïve genotype 1, patients were randomized to receive either 
triple therapy with simeprevir plus PEG-IFN and RBV using a response-guided therapy 
(RGT) approach or standard of care (48 weeks of PEG-IFN and RBV with placebo control). 
SVR12 rates were 81% in the simeprevir arm versus 50% in the control arm. The majority of 
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simeprevir-treated patients met the RGT and received 24 weeks of treatment and 86% of these 
patients achieved an SVR12.
Simeprevir also enhanced SVR in treatment-experienced patients. In the ASPIRE trial [47] 
treatment-experienced patients (with prior failure to PEG/RBV) were randomized to receive 
placebo plus PEG/RBV, or one of six regimens consisting of SMV plus PEG-IFN-α-2a plus 
ribavirin. In the SMV-treated patients, the SVR 24 rates ranged from 61 to 80% (according to 
the regimen used), which was significantly higher than the 23% SVR in patients treated with 
PEG-IFN/RBV. The safety profile observed among patients in the simeprevir arm was similar 
to the safety profile for patients in the placebo arm. These results were supported by those 
of another clinical trial conducted on treatment-experienced HCV genotype 1 patients with a 
history of viral relapse. The overall SVR12 in patients treated with SIM/PEG-IFN/RBV was of 
79% compared to 36% for the peginterferon plus ribavirin arm. Patients with advanced fibro-
sis (F3-F4 by METAVIR) also had superior SVR12 rates with the addition of simeprevir (73% 
SVR12 compared with 24% in control arm) [48].
The efficacy of SIM/PEG-IFN/RBV in treatment-naïve and treatment-experienced patients 
with chronic HCV genotype 4 was evaluated in the RESTORE trial. Overall, 65.4% of the 
patients achieved an SRV12. The SVR12 rates varied with treatment group being 83% in treat-
ment-naïve, 86% in treatment-experienced with prior relapse, 60% in prior partial responders, 
and 40% in prior null responders [49].
These trials showed that simeprevir-based/PEG-IFN/RBV triple therapy was effective, well-
tolerated, and safe. However, the fast-paced HCV drug discovery paved the way to new 
interferon-free combinations which combine efficacy, safety, and convenience. Thus, SMV 
was included with other DAAs such as sofosbuvir to form one of the earliest interferon-free 
combinations (discussed later).
Danoprevir (DNV) is a highly selective and potent second-wave inhibitor of HCV NS3/4A 
protease. Coadministration of 100 mg of ritonavir with DNV has been shown to optimize 
the pharmacokinetics of DNV, allowing for lower dosing and better antiviral activity The 
DAUPHINE trial [50] evaluated three different dosages of DNV/r: 50, 100, and 200 mg dano-
previr, boosted with 100 mg ritonavir, consumed twice a day for 24 weeks. A study arm also 
explored danoprevir/r 100/100 mg, in a response-guided therapy (RGT) algorithm, in which 
patients reaching an RVR received a total of 12 weeks of treatment. Overall, the better SVR rates 
were achieved in higher dosage arms compared to lower dosage arms. SVR rates decreased 
with decreasing dosage of danoprevir/r as follows: 89.1, 78.5, and 69.1% [50]. Faldaprevir was 
evaluated in IFN-free regimen in combination with deleobuvir, an NS5B no nucleoside poly-
merase inhibitor and ribavirin, in HCV-1b patients. The combination was highly efficacious, 
with 95% achieving SVR12 including patients with compensated cirrhosis [51].
Taken together, the second-wave, first-generation protease inhibitors offer several benefits 
over the first-generation PIs, TVR, and BOC in terms of less side effect profile and more con-
venient dosing. However, these preparations still have low genetic barrier to resistance par-
ticularly for HCV-1a.
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4.2.1.3. Second-generation protease inhibitors
Recent second-generation PIs such as the macrocyclic compound grazoprevir offer several 
benefits over earlier protease inhibitors, including fewer drug-drug interactions, improved 
dosing schedules, and less frequent and less severe side effects. Grazoprevir is distinct from 
earlier-generation protease inhibitors in potency against a broader array of HCV genotypes, 
as well as its activity against some of the major resistance-associated variants (R155K and 
D168Y) resulting from failure with first-generation protease inhibitors. Grazoprevir is avail-
able in combination with the NS5A inhibitor elbasvir. Elbasvir/grazoprevir (Zepatier) [52] is 
available as fixed dose tablets (50/100 mg) are prescribed as one tablet orally once daily, with 
or without food. The treatment duration and whether to take with or without ribavirin are 
dependent on genotypes and other patient variables [53].
The C-EDGE treatment-naïve trial assessed the safety and efficacy of the fixed-dose combina-
tion of elbasvir-grazoprevir (50/100 mg) in patients with genotype 1, 4, or 6 hepatitis C infection, 
with or without compensated cirrhosis. The overall SVR12 rate was 95%, with rates of 92% for 
genotype 1a, 99% for genotype 1b, 100% for genotype 4, and 80% for genotype 6. No statistically 
significant difference in SVR12 was found between cirrhotic and noncirrhotic patients [54]. The 
C-EDGE CO-STAR trial enrolled treatment-naïve patients who inject drugs and were infected 
with chronic HCV genotype 1, 4, or 6. In this difficult to treat cohort, the SVR12 were 95% [55].
Treatment-naïve patients with compensated cirrhosis and treatment-experienced patients with 
a prior null response to PEG plus RBV were randomized to receive elbasvir plus grazoprevir, 
with or without ribavirin, for 12 or 18 weeks. The SVR12 rates ranged between 90 and 97% in 
cirrhotics and 94% in null responder cirrhotic patients. The SVR12 was 100% for genotype 1b. 
No additional benefit was achieved by adding ribavirin to elbasvir plus grazoprevir in a subset 
of patients [56]. Treatment-experienced patients with genotype 1 HCV with previous failure of 
peg interferon/ribavirin (PR) and an earlier-generation protease inhibitor (BOC, TPV, or SIM) 
achieved SVR 24 of 96% when treated with elbasvir plus grazoprevir and RBV [57].
In the C-EDGE coinfection trial, patients with chronic hepatitis C genotype 1, 4, or 6 and HIV 
coinfection received elbasvir-grazoprevir once daily for 12 weeks. Patients were on antiretrovi-
ral therapy with HIV viral suppression and the median CD4 cell count was 568 cells/mm3. The 
overall SVR12 rate was 96, with the breakdown by genotype SVR12 rates were 96.5, 95.5, and 
96.4% for genotypes 1a, 1b, and 4, respectively. All cirrhotic patients achieved an SVR12 [58].
Thus, zepatier is active against a broad array of HCV genotypes including genotypes 1, 4, 
6, as well as some of the major resistance-associated variants (R155K and D168Y) resulting 
from failure with first-generation protease inhibitors. Elbasvir/grazoprevir is generally well 
tolerated; however, the adverse effects reported include headache, nausea, fatigue, decreased 
appetite, anemia, pyrexia, and elevations of ALT.
4.2.2. NS5B nucleoside polymerase inhibitors (NPIs)
NS5B is an RNA-dependent RNA polymerase (RdRp) involved in posttranslational process-
ing which is vital for HCV replication. NPIs are analogs of natural substrates that bind the 
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active site of NS5B and terminate viral RNA chain generation. Given that the structure of 
NS5B is highly conserved across all HCV genotypes, NPIs are effective against all genotypes. 
NPIs show high antiviral activities in all genotypes and provide a high genetic barrier to 
resistance. Thus, NPIs are included in several efficacious all-oral combination therapies. 
Polymerase inhibitors are categorized according to their mode of action and specificity into 
NPIs and NNPIs. These two classes generally differ in specificity. Nucleoside inhibitors (NIs) 
bind to the catalytic site of the RNA polymerase causing chain termination. Nonnucleoside 
inhibitors bind to a less conserved site resulting in a conformational change that distorts the 
positioning of residues binding RNA resulting in inhibition of polymerization [59, 60].
4.2.2.1. Sofosbuvir (sovaldi)
Sofosbuvir is a nucleoside analog inhibitor of hepatitis C virus NS5B polymerase. The triphos-
phate form of sofosbuvir mimics the natural cellular uridine nucleotide and is incorporated 
by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain 
termination. Sofosbuvir is a prodrug which is rapidly converted after oral intake to GS-331007 
which is taken up by hepatocytes. The cellular kinases convert GS-331007 to its pharmacologi-
cally active uridine analog 5′-triphosphate form (GS-461203) that is incorporated by the HCV 
RNA polymerase into the elongating RNA primer strand, resulting in chain termination. 
Sofosbuvir is a potent pangenotypic NS5B polymerase inhibitor with a high barrier to resis-
tance. It is available as 400 mg tablets administered once a day with or without food. The dis-
covery of sofosbuvir has been a breakthrough in HCV treatment. Currently, SOF represents 
the backbone of several interferon-free regimens for the treatment of chronic hepatitis caused 
by various HCV genotypes. Excretion of sofosbuvir is through the kidney (80%) [58, 59, 61].
4.2.3. Efficacy of sofosbuvir plus peginterferon and ribavirin
The ATOMIC and ELECTRON (Arms 1-8 studies) [62, 63] established the effectiveness of a 
12-week course of sofosbuvir plus peginterferon and ribavirin in treatment-naïve patients 
with HCVgenotype-1 with SVR rates ranging between 87 and 100%. In genotypes 3, the SVR 
12 rates were 71% with the 16-week SOF plus RBV regimen, 84% with 24 weeks of SOV plus 
RBV, and 93% with 12 weeks of SOF plus RBV plus PEG-IFN. For the patients with genotype 
2 infections, the SVR 12 rates were 87% with the 16-week SOF plus RBV regimen, 100% with 
24 weeks of SOF plus RBV, and 94% with 12 weeks of SOF plus RBV plus PEG-IFN [64].
4.2.4. Efficacy of interferon-free sofosbuvir regimen
4.2.4.1. Sofosbuvir (SOF) and simeprevir (SIM) combination (Olysio)
This combination is the earliest interferon-free regimen that reached optimal results in terms 
of SVR. Trials showed efficacy and safety of this drug combination in treatment-naïve and 
treatment-experienced patients across several genotypes. The OPTIMIST-1 trial evaluated the 
efficacy of sofosbuvir plus simeprevir for 8 or 12 weeks in treatment naive or experienced 
patients with chronic HCV genotype 1 infection without cirrhosis. The sustained response 
rates were 97% in patients treated for 12 weeks and the SVR was 83% in patients treated for 8 
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weeks. These findings were further confirmed in the OPTIMIST-2 trial which demonstrated 
that 12-week regimen of SOF plus SIM is effective in treatment-naïve and treatment-experi-
enced patients with cirrhosis and HCV genotype 1 infection, with the exception that patients 
with genotype 1a and the baseline Q80K mutation have SVR rates of only 74% [66].
A large cohort prospective study in genotype 1 patients treated with SOF plus SIM for 12–16 
weeks showed that the overall SVR rate was 84%. Model-adjusted estimates demonstrated that 
patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were 
less likely to achieve an SVR. Addition of ribavirin enhances SVR rates in such patients [67].
Taken together, several clinical trials demonstrate that all-oral 12-week regimen of simeprevir 
plus sofosbuvir is effective and well tolerated in treatment-naïve and treatment-experienced 
HCV genotype 1 patients without and with cirrhosis. Ribavirin may be needed in patients 
with decompensation, and previous protease inhibitor treatment failure. The frequent adverse 
events include fatigue, headache, nausea, rashes, and insomnia. Serious adverse events and 
treatment discontinuation occur in only 3% of patients.
4.2.4.2. Sofosbuvir with the NS5A inhibitor ledipasvir (Harvoni)
• Treatment-naïve and treatment-experienced genotype 1 patients
Gane et al. [68] evaluated an all-oral regimen comprising sofosbuvir with ledipasvir or the 
NS5B nonnucleoside inhibitor GS-9669 in patients with genotype 1 HCV infection. Sofosbuvir 
(400 mg once daily) and ledipasvir (90 mg once daily) plus ribavirin were given for 12 weeks to 
treatment-naïve patients and prior null responders. Sofosbuvir and GS-9669 (500 mg once daily) 
plus ribavirin were given for 12 weeks to treatment-naïve patients and prior null responders. 
Additionally, prior null responders with cirrhosis were randomly assigned to groups given a 
fixed-dose combination of sofosbuvir and ledipasvir, with ribavirin or without ribavirin and 
a group of treatment-naïve patients received sofosbuvir, ledipasvir, and ribavirin for 6 weeks. 
SVR12 was 100, 92, and 68% in treatment-naïve patients receiving sofosbuvir, those receiving 
SOV, ledipasvir, ribavirin, GS-9669, and ribavirin and patients receiving 6 weeks of sofosbu-
vir, ledipasvir, and ribavirin, respectively. All noncirrhotic prior null responders receiving 12 
weeks of sofosbuvir along with another DAA plus RBV achieved SVR12 of 100%.
In the NIAID SYNERGY (genotype 1 study) [69], treatment-naïve patients with genotype 1 
chronic HCV were randomized to receive either ledipasvir-sofosbuvir for 12 weeks; or ledi-
pasvir-sofosbuvir (90-400 mg) plus the nonnucleoside NS5B inhibitor GS-9669 (500 mg once 
daily) for 6 weeks, or ledipasvir-sofosbuvir (90-400 mg) plus the NS3/4A protease inhibitor 
GS-9451 (80 mg once daily) for 6 weeks. Patients in the 12-week ledipasvir-sofosbuvir arm 
with any stage of fibrosis could be enrolled in the study. The SVR12 rates were 100, 95, and 
95% in the ledipasvir-sofosbuvir arm, the ledipasvir-sofosbuvir plus GS-9669 group, and the 
ledipasvir-sofosbuvir plus GS-9451 group, respectively.
A trial [70] evaluated 8- and 12-week courses of the fixed-dose combination of ledipasvir (90 
mg) and sofosbuvir (400 mg), with or without ribavirin in treatment-naïve and treatment-
experienced patients with chronic HCV genotype 1 infection. In all of the five study arms, 
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SVR12 was achieved in 95–100% of patients. The regimen of ledipasvir-sofosbuvir was well 
tolerated; only one patient had a serious adverse event of anemia, thought to be related to 
ribavirin. A recent large study that enrolled 4365 genotype 1, treatment-naïve, HCV-infected 
patients treated with LDV/SOF±RBV demonstrated SVR rates of 91.3 and 92.0% (3191/3495) 
for LDV/SOF and LDV/SOF+RBV, respectively [71].
Thus, the combination of ledipasvir-sofosbuvir with or without ribavirin is highly effective in 
treatment-naïve and treatment-experienced patients with chronic HCV genotype 1.
• Sofosbuvir- ledipasvir in HCV nongenotype 1 patients
Patients with genotype 3 and 6 achieved good SVR rates when treated with ledipasvir-sofos-
buvir. The SVR 12 responses in treatment-naïve patients with genotype 3 were superior in 
the regimen with ribavirin (100%) than without ribavirin (64%). Among the treatment-expe-
rienced patients, 82% of treated ledipasvir-sofosbuvir plus ribavirin achieved an SVR 12 and 
the SVR 12 rate was 96% in the patients with genotype 6 [72].
The NIAID SYNERGY (Genotype 4) trial enrolled treatment-naïve and treatment-experienced 
patients with genotype 4 chronic HCV to receive ledipasvir-sofosbuvir for 12 weeks. Patients 
with compensated cirrhosis were allowed to enroll in the study. Overall, in the intent-to-treat 
SVR was 95% [73]. A recent study that enrolled treatment-naïve and -experienced patients with 
chronic HCV genotype 4 revealed SVR12 of 78% in patients treated with ledipasvir-sofosbuvir for 
12 weeks and SVR 12 in patients treated with 24 weeks [74]. These findings suggest that further 
studies are still needed to optimize ledipasvir-sofosbuvir therapy in patients with different stages 
of chronic HCV genotype 4. To date, the efficacy and duration of DAAs in HCV genotype 4 have 
not been adequately studied and further trials are required to optimize therapy in this genotype.
A clinical trial assessed response to ledipasvir-sofosbuvir in 41 patients with chronic HCV 
genotype 5 (21 treatment-naïve and 20 treatment-experienced). The overall SVR12 was 95% 
in treatment-naïve and treatment-experienced patients, while the SVR12 was 97% in patients 
without cirrhosis and 89% in patients with cirrhosis [75].
• HCV and HIV coinfected patients
The ERADICATE trial investigated the safety and efficacy of a 12-week regimen of ledipasvir-
sofosbuvir in HCV treatment-naïve patients with genotype 1 chronic hepatitis C who are 
coinfected with HIV. Patients on antiretroviral therapy were allowed to receive tenofovir-
emtricitabine plus either efavirenz, raltegravir, rilpivirine, rilpivirine plus raltegravir, or efa-
virenz plus raltegravir. In patients taking antiretroviral therapy, SVR12 was 97% [76]. The 
SVR12 was 96.4% in German HIV-HCV coinfected patients [77]. A study investigated the effi-
cacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in HCV/HIV-coinfected 
patients who relapsed after receiving 12 weeks of ledipasvir/sofosbuvir therapy. The SVR12 
was 89% suggesting that ledipasvir/sofosbuvir can be an effective salvage therapy for patients 
for whom direct-acting antiviral treatment has failed [78].
Thus, ledipasvir-sofosbuvir is well tolerated and effective in patients with genotype 1 HCV 
and HIV coinfection. However, more studies are required to investigate the efficacy and safety 
of ledipasvir/sofosbuvir in treatment of HIV patients infected with various HCV genotypes. 
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Importantly the drug-drug interactions between ledipasvir/sofosbuvir and antiretroviral ther-
apy need extensive investigations on large cohorts.
-Retreatment of sofosbuvir failures
In the NIAID retreatment of sofosbuvir failures trial [79], patients with genotype 1 HCV who 
previously had failed a 24-week course of sofosbuvir plus ribavirin achieved SVR12 ranged 
between 98 and 100% when retreated with fixed-dose combination of ledipasvir-sofosbuvir 
for 12 weeks. Despite the small sample size in this study, the trial showed that 12-week regi-
men of ledipasvir-sofosbuvir without or with ribavirin was well tolerated and shows promise 
as a treatment option for patients with prior sofosbuvir failure.
4.2.4.3. Sofosbuvir/velpatasvir (Epclusa)
Sofosbuvir-velpatasvir (sofosbuvir 400 mg plus velpatasvir 100 mg) is an oral fixed-dose combi-
nation of sofosbuvir, and the novel NS5A replication complex inhibitor, velapatasvir. Velpatasvir 
(formerly GS-5816) has potent in vitro anti-HCV activity across all genotypes at the picomolar 
level. The combination of sofosbuvir-velpatasvir is the first once-daily single-tablet regimen with 
pangenotypic activity. Sofosbuvir-velpatasvir is indicated for patients with chronic HCV geno-
type 1 through 6 [80]. A clinical trial [81] assessed the efficacy and safety of the combination of 
the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A 
protease inhibitor GS-9857 in patients with hepatitis C virus (HCV) genotype 1 infection. Among 
treatment-naïve patients without cirrhosis, the SVR rates were 71 and 100% after 6 and 8 weeks 
of treatment, respectively. Among treatment-naïve patients with cirrhosis, 94% achieved SVR12 
after 8 weeks therapy and 81% after 8 weeks of treatment with ribavirin. The SVR12 rates were 
100% in DAA-experienced patients without cirrhosis and with cirrhosis, respectively.
Sofosbuvir-velpatasvir showed high efficacy in non-1 genotypes. ASTRAL-2 study demon-
strated that the SVR12 was 99% treatment-naïve and treatment-experienced patients infected 
with HCV genotype 2 [82]. Among HCV with chronic HCV genotype 3 treated with sofosbuvir-
velpatasvir, the ASTRAL-3 trial showed that the SVR12 rate were 93% for treatment-naïve and 
89% for treatment-experienced patients [83]. SVR12 was 100% in patients with chronic HCV gen-
otype 4 [84]. The ASTRAL-4 studies [82] demonstrated that sofosbuvir/velpatasvir plus ribavirin 
were effective in achieving a high SVR12 rate in patients with decompensated cirrhosis [85].
The ASTRAL-5 study investigated the safety and efficacy of 12 weeks sofosbuvir-velpatasvir in 
patients with HIV and HCV coinfection. Enrolled patients were infected with genotype 1, 2, 3, 4, 
or 6 HCV infection; 18% had compensated cirrhosis and 29% were treatment-experienced. The 
mean CD4 count was 583 cells/mm3 and all patients had HIV viral suppression. The antiretroviral 
regimens included tenofovir disoproxil fumarate (DF). The overall SVR12 rate was 95%. The pres-
ence of cirrhosis or treatment experience did not negatively influence treatment response [86].
4.2.5. Nonstructural protein 5A (NS5A) inhibitors
The NS5A protein is essential for replication and assembly of HCV. Inhibitors of NS5A block 
viral production at an early stage of assembly, so that no viral RNA or nucleocapsid protein 
is released [87]. Therefore, agents that block NS5B activity (polymerase inhibitors) inhibit the 
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virus's RdRp [87]. Nucleoside inhibitors (NIs) bind to RdRp’s active site, whereas the non-
nucleoside inhibitors (NNIs) bind to the enzyme outside the active site, inducing conforma-
tional changes that downregulated RdRp’s activity. As a result of mechanistic and potency 
differences, the NIs tend to have broad potency against multiple HCV genotypes and are less 
likely to select for resistant strains than are the NNIs [88]. Cyclophilin is a host protein that 
interacts with NS5B and appears to promote the HCV protein’s ability to bind.
4.2.5.1. Daclatasvir (Daklinza)
Daclatasvir HCV is first-in-class inhibitor of the nonstructural viral protein 5A (NS5A), a 
phosphoprotein that plays an important role in hepatitis C replication. The exact mechanism 
by which daclatasvir inhibits the NS5A replication complex is unclear, but it is believed that 
daclatasvir inhibits viral RNA replication and virion assembly. It may also inhibit phosphor-
ylation of the NS4A, and therefore the formation and activation of the HCV replication com-
plex. Based on in vitro data, daclatasvir has shown activity against HCV genotypes 1 through 
6, with EC50 values ranging from picomolar to low nanomolar against wild-type HCV [89].
When used in combination with sofosbuvir, with or without ribavirin, daclatasvir showed 
high efficacy in pangenotypic all-oral regimen. According to the results of the AI444040 and 
ALLY-3 trials [90, 91], a 12-week regimen of daclatasvir plus sofosbuvir in patients with 
chronic HCV genotype 1 or 3 infection without cirrhosis resulted in high SVR12 rates, regard-
less of prior treatment experience. The ALLY-3 [91] trial demonstrated high SVR12 rates with 
a 12- or 16-week regimen of daclatasvir plus sofosbuvir and ribavirin in patients with chronic 
HCV genotype 3 infections and advanced fibrosis or compensated cirrhosis. A daclatasvir 
plus sofosbuvir-based regimen demonstrated efficacy in patients with chronic HCV genotype 
1, 3, or 4 infection and advanced cirrhosis or posttransplant recurrence in the ALLY-1 trial [92], 
and in patients coinfected with HCV genotype 1, 3, or 4 and HIV-1 in the ALLY-2 trial [93].
Daclatasvir plus sofosbuvir with or without ribavirin was generally well tolerated. Fatigue, 
headache, nausea, and diarrhea were the adverse events reported in some patients treated 
with daclatasvir [91–93]. Daclatasvir and sofosbuvir combination can potentially cause seri-
ous bradycardia when coadministered with amiodarone. Given that daclatasvir is a substrate 
of CYP3A, it is contraindicated for use with drugs that are strong inducers of CYP3A, includ-
ing phenytoin, carbamazepine, and rifampin [94].
Data from clinical trials showed resistance-associated substitutions in the NS5A gene [95]. 
Thus, the AASLD/IDSA HCV Guidance Panel recommends testing for these substitutions 
when NS5A inhibitors fail [96]. Baseline NS5A polymorphisms may also impact the emer-
gence of NS5A resistance [96].
Taken together, daclatasvir plus sofosbuvir with or without ribavirin is an important option 
for use in treatment-naïve or treatment-experienced patients with chronic HCV genotype 1, 3, 
or 4 infections, including patients with advanced liver disease, posttransplant recurrence, and 
HIV-1 coinfection. Daclatasvir with sofosbuvir is a particularly useful ribavirin-free oral option 
for genotype 3 patients. Testing for the presence of NS5A polymorphisms is recommended at 
baseline for patients with HCV genotype 1a prior to initiation of treatment with in patients 
with genotype 1a and cirrhosis prior to sofosbuvir plus daclatasvir treatment.
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4.2.5.2. Liedipasvir
Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays a critical 
role in viral replication, assembly, and secretion [97]. The results of clinical trials assessing 
ledipasvir combinations with SOF have been discussed previously.
Coadministration of amiodarone and ledipasvir-sofosbuvir is not recommended given that 
severe cases of symptomatic bradycardia have been reported. Ledipasvir-sofosbuvir has signifi-
cant drug-drug interactions with P-gp inducers such as rifampin that may cause a significant 
reduction in levels of ledipasvir and sofosbuvir and reduced efficacy of ledipasvir-sofosbuvir [97].
4.2.6. Ombitasvir-paitaprevir-ritonavir-dasabuvir (Viekira Pak)
The four medications: ombitasvir, paritaprevir, ritonavir, and dasabuvir are combined as a 
fixed-dose tablet and the dasabuvir is a separate tablet. Ombitasvir is an NS5A inhibitor with 
potent pangenotypic picomolar antiviral activity, paritaprevir is an inhibitor of the NS3/4A 
serine protease, and dasabuvir is a nonnucleoside NS5B polymerase inhibitor. Ritonavir is a 
potent inhibitor of CYP3A4 enzymes and is used as a pharmacologic booster for paritapre-
vir—it significantly increases peak and trough paritaprevir plasma concentrations, as well as 
the area under the curve of paritaprevir [98].
PEARL III trial demonstrated the SVR12 rate of 99.5% in treatment-naïve patients with chronic 
HCV genotype 1b treated with ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavi-
rin group and 99% in patients who received ombitasvir-paritaprevir-ritonavir and dasabuvir 
without ribavirin [99]. The TURQUOISE trial assessed the efficacy and safety of ombitasvir, 
paritaprevir, ritonavir, and dasabuvir plus RBV in HCV/HIV-1 coinfected patients for 12 or 24 
weeks. The study enrolled HCV treatment-naïve or PEG-IFN/RBV-experienced patients, with 
or without Child-Pugh A cirrhosis. Patients with CD4+ count ≥200 cells/mm3 or CD4+ % ≥14%, 
and plasma HIV-1 RNA suppressed on a stable atazanavir- or raltegravir-inclusive antiretro-
viral (ART) regimen were included. Among patients treated with 3D+RBV for 12 weeks, 93.5% 
achieved SVR12. Among patients receiving 24 weeks of treatment, 96.9% achieved EOTR; the 
most common AEs were fatigue, insomnia, and nausea. Elevation in total bilirubin was the most 
common laboratory abnormality, occurring predominantly in patients receiving atazanavir.
This combination was effective liver transplant recipients who have recurrent hepatitis C 
genotype 1 infection [101]. In patients with stage 4 or 5 renal disease and patients on dialysis 
treated with ombitasvir-paritaprevir-ritonavir and dasabuvir., EOT response was 100% and 
SVR12 response was achieved in 85% of patients with genotype 1b [102].
5. Treatment of different HCV genotypes
According to the 2016 HCV treatment guidelines of the American Association for the Study 
of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) [96] and 
European Association of Study of Liver Diseases (EASL) [99], chronic HCV due to any geno-
type can be efficiently treated using all-oral DAA interferon-free regimens.
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5.1. HCV genotype 1 (Figure 4)
Optimizing the regimen of therapy for chronic HCV genotype 1 depends on several factors 
such as whether the patient is treatment naïve or experienced and the previous therapies 
provided and the status of resistance in some cases. Given the high cost of IFN-free regimen 
and difficulties in access to this therapy in various countries, it is necessary to tailor therapy 
according to the patient population treated and the available therapies.
5.2. Ledipasvir-sofosbuvir combination
• Treatment-naïve patients with or without compensated cirrhosis patients are treated with 
a fixed-dose combination of sofosbuvir and ledipasvir for 12 weeks.
• Therapy may be shortened to 8 weeks in patients with a viral load <6 million IU/ml.
• Treatment-experienced, DAA-naïve patients infected with genotype 1b with or without 
compensated cirrhosis are treated with the fixed-dose combination of sofosbuvir and ledi-
pasvir for 12 weeks without ribavirin.
• Treatment-experienced, DAA-naïve patients infected with genotype 1a with or without 
compensated cirrhosis are treated with the fixed-dose combination of sofosbuvir and ledi-
pasvir for 12 weeks with daily weight-based ribavirin (1000 or 1200 mg in patients <75 kg 
or =75 kg, respectively).
• If there is a contraindication to ribavirin, the treatment-experienced, DAA-naïve patients 
are treated with Harvoni for 24 weeks.
Figure 4. Treatment of HCV genotype 1.
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• Treatment-experienced, DAA-naïve patients infected with genotype 1a with or without 
compensated cirrhosis who have NS5A RASs and resistance to ledipasvir (M28A/G/T, 
Q30E/G/H/K/R, L31M/V, P32L/S, H58D, and/or Y93C/H/N/S) are treated with the fixed-
dose combination of sofosbuvir and ledipasvir for 12 weeks with ribavirin.
5.3. Sofosbuvir-velpatasvir
• Genotype 1a, regardless of the presence of cirrhosis: sofosbuvir-velpatasvir is prescribed 
for 12 weeks without ribavirin in treatment naïve or treatment experienced.
• Genotype 1b, regardless of the presence of cirrhosis: sofosbuvir-velpatasvir is prescribed 
for 12 weeks without ribavirin in treatment naïve or treatment experienced.
5.4. Elbasvir-grazoprevir
Elbasvir-grazoprevir (50 mg/100 mg) therapy in chronic hepatitis C genotypes 1 is tailored 
according prior treatment experience and the presence of baseline polymorphisms at amino 
acid positions 28, 30, 31, or 93.
• Genotype 1a, treatment-naïve or peginterferon/ribavirin-experienced with no baseline 
NS5A polymorphisms: elbasvir-grazoprevir is given for 12 weeks.
• Genotype 1a, treatment-naïve or peginterferon/ribavirin-experienced with baseline NS5A 
polymorphisms: elbasvir-grazoprevir plus ribavirin is prescribed for 16 weeks.
• Genotype 1b, treatment-naïve or peginterferon/ribavirin-experienced: elbasvir-grazopre-
vir is given for 12 weeks.
• Genotype 1a or 1b, peginterferon/ribavirin/protease inhibitor-experienced: elbasvir-grazo-
previr plus ribavirin is given for 12 weeks.
5.4.1. Sofosbuvir and daclatasvir
In genotype 1 infections, sofosbuvir and daclatasvir are used with or without ribavirin 
depending on the patient population
• Genotype 1, without cirrhosis: daclatasvir plus sofosbuvir are prescribed for 12 weeks.
• Genotype 1 with compensated cirrhosis: daclatasvir plus sofosbuvir are given for 12 weeks.
• Genotype 1 with decompensated (Child-Pugh B or C) cirrhosis: daclatasvir plus sofosbuvir 
plus ribavirin are given for 12 weeks.
5.4.2. Ombitasvir-paritaprevir-ritonavir-dasabuvir
In regions where this combination is available, the therapeutic strategy is recommended as 
follows:
• Genotype 1a, without cirrhosis: ombitasvir-paritaprevir-ritonavir and dasabuvir plus riba-
virin are prescribed for 12 weeks.
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• Genotype 1a, with cirrhosis: ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavi-
rin are prescribed for 24 weeks.
• Genotype 1b, without cirrhosis: ombitasvir-paritaprevir-ritonavir and dasabuvir are pre-
scribed for 12 weeks.
• Genotype 1b, with cirrhosis: ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavi-
rin are prescribed for 12 weeks
Thus, Viekira Pak prescribed with ribavirin except in patients without cirrhosis
Genotype 2 (Figure 5)
Chronic HCV genotype 2 treatment-naïve or treatment-experienced patients are treated with 
either with aofosbuvir/velpatasvir for 12 weeks without ribavirin or sofosbuvir and daclatas-
vir without ribavirin.
Figure 5. Treatment of HCV genotype 2.
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HCV genotype 3 (Figure 6)
Chronic HCV genotype 2 treatment-naïve patients are treated with either sofosbuvir/velpatas-
vir for 12 weeks without ribavirin or sofosbuvir and daclatasvir without ribavirin. Ribavirin is 
added for the therapy of treatment-experienced patients.
HCV genotype 4 (Figure 7)
Treatment-naïve patients with chronic hepatitis C genotype 4 can be treated by one of the fol-
lowing regimen according to availability:
 - Sofosbuvir (400 mg)/ledipasvir (90 mg) for 12 weeks without ribavirin is prescribed for 
treatment-naïve patients with or without compensated cirrhosis. In treatment-experienced 
patients, ribavirin is added as a daily weight-based dose (1000 or 1200 mg in patients <75 
kg or =75 kg, respectively). Sofosbuvir and ledipasvir for 24 weeks is recommended for 
treatment-experienced patients with or without compensated cirrhosis with contraindica-
tions to the use of ribavirin or with poor tolerance to ribavirin.
 - Sofosbuvir/velpatasvir combination for 12 weeks without ribavirin is given to treatment-
naïve and treatment-experienced chronic HCV genotype 4 patients with or without com-
pensated cirrhosis.
 - Ombitasvir (12.5 mg), paritaprevir (75 mg), and ritonavir (50 mg) is given as two tablets 
once daily without dasabuvir to patients infected with HCV genotype 4 with and without 
compensated cirrhosis.
Figure 6. Treatment of HCV genotype 3.
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 - Grazoprevir (100 mg) and elbasvir (50 mg) without ribavirin is prescribed as one tablet 
daily to treatment-naïve patients infected with genotype 4 with or without compensated 
cirrhosis. In treatment-experienced patients infected with genotype 4 with or without com-
pensated cirrhosis with an HCV RNA level at baseline >800,000 IU/ml are treated with 
grazoprevir and elbasvir for 16 weeks with daily weight-based ribavirin (1000 or 1200 mg 
in patients <75 kg or =75 kg, respectively).
 - Sofosbuvir (400 mg) and daclatasvir (60 mg) is given to treatment-naïve patients with or 
without cirrhosis should be treated with the combination of sofosbuvir and daclatasvir 
for 12 weeks without ribavirin. Ribavirin (1000 or 1200 mg in patients <75 kg or =75 kg) is 
added for treatment-experienced patients with or without compensated cirrhosis.
Figure 7. Treatment of HCV genotype 4.
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HCV genotype 5 or 6 (Figure 8)
Treatment-naïve patients with or without compensated cirrhosis patients with chronic HCV 
genotype 5 or 6 are treated with sofosbuvir and ledipasvir for 12 weeks without ribavirin. 
Treatment-experienced patients with or without compensated cirrhosis are treated with the 
combination of sofosbuvir and ledipasvir for 12 weeks with daily weight-based ribavirin 
(1000 or 1200 mg in patients <75 kg or =75 kg, respectively. Treatment-naïve and treatment-
experienced patients with or without compensated cirrhosis are treated with the fixed-dose 
combination of sofosbuvir and velpatasvir for 12 weeks without ribavirin, and ribavirin is 
added in patients with treatment-experienced patients.
Figure 8. Treatment of HCV genotype 5, 6. Note: Ledipasvir: LDV; Sofosbuvir: SOF; Ribavirin: RBV; Simeprevir: SIM, 
Velpatasvir: VEL; Elbasvir: EBR; Grazoprevir: GZR; Daclatasvir: DAC; Ombitasvir: OBV; Paritaprevir: PTV; Rintonavir: r.
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6. Patients with HCV and HIV coinfection
Patients with HCV and HIV coinfection are treated according to genotype and prior treatment 
status as follows [96, 99, 100, 101]:
(1) Genotype 1a, treatment-naïve patients may be treated with any of the following regimen:
a. Sofosbuvir/ledipasvir for 12 weeks without ribavirin
b. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
c. Ombitasvir/paritaprevir/ritonavir and dasabuvir for 12 weeks with ribavirin
d. Grazoprevir/elbasvir for 12 weeks without ribavirin if HCV RNA=800,000 IU/ml or 
16 weeks with ribavirin if HCV RNA >800,000 IU/ml
e. Sofosbuvir/daclatasvir for 12 weeks without ribavirin
Genotype 1a, treatment-experienced patients may be treated with any of the following 
regimen:
a. Sofosbuvir/ledipasvir for 12 weeks with ribavirin or 24 weeks without ribavirin
b. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
c. Ombitasvir/paritaprevir/ritonavir and dasabuvir for 12 weeks with ribavirin
d. Grazoprevir/elbasvir for 12 weeks without ribavirin if HCV RNA=800,000 IU/ml or 
16 weeks with ribavirin if HCV RNA >800,000 IU/ml
e. Sofosbuvir/daclatasvir for 12 weeks with ribavirin or 24 weeks without ribavirin
(2) Genotype 1b, treatment-naïve and treatment-experienced patients may be treated with 
any of the following regimen:
a. Sofosbuvir/ledipasvir for 12 weeks without ribavirin
b. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
c. Ombitasvir/paritaprevir/ritonavir and dasabuvir for 12 weeks with ribavirin
d. Grazoprevir/elbasvir for 12 weeks without ribavirin
e. Sofosbuvir/daclatasvir for 12 weeks without ribavirin
(3) Genotype 2, treatment-naïve and treatment-experienced patients may be treated with any 
of the following regimen:
a. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
b. Sofosbuvir/daclatasvir for 12 weeks without ribavirin
(4) Genotype 3, treatment-naïve and treatment-experienced patients may be treated with any 
of the following regimen:
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a. Sofosbuvir/velpatasvir for 12 weeks with ribavirin or 24 weeks without ribavirin
b. Sofosbuvir/daclatasvir for 12 weeks with ribavirin
(5) Genotype 4 treatment-naïve patients may be treated with any of the following regimen:
a. Sofosbuvir/ledipasvir for 12 weeks without ribavirin
b. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
c. Ombitasvir/paritaprevir/ritonavir with ribavirin for 12 weeks
d. Grazoprevir/elbasvir for 12 weeks without ribavirin
e. Sofosbuvir/daclatasvir for 12 weeks without ribavirin
f. Sofosbuvir and simeprevir for 12 weeks without ribavirin
Genotype 4 treatment-experienced patients may be treated with any of the following 
regimen:
g. Sofosbuvir/ledipasvir for 12 weeks with ribavirin and 24 weeks with ribavirin
h. Sofosbuvir/velpatasvir for 12 weeks without ribavirin
i. Ombitasvir/paritaprevir/ritonavir with ribavirin for 12 weeks
j. Grazoprevir/elbasvir for 12 weeks without ribavirin if HCV RNA =800,000 or 16 
weeks with ribavirin if HCV RNA >800,000 IU/ml
k. Sofosbuvir/daclatasvir for 12 weeks with ribavirin or 24 weeks without ribavirin
l. Sofosbuvir and simeprevir for 12 weeks with ribavirin or 24 weeks without ribavirin
Daclatasvir, dose requirement is needed with ritonavir-boosted atazanavir and efavirenz or 
etravirine. Simeprevir should be used with antiretroviral drugs with which it does not have 
clinically significant interactions. In addition, it is recommended daily fixed doses of com-
bined sofosbuvir (400 mg)/velpatasvir (100 mg) and of ledipasvir (90 mg)/sofosbuvir (400 
mg). For combinations expected to increase tenofovir levels, baseline and ongoing assessment 
for tenofovir nephrotoxicity is recommended. Regarding HCV/HIV individuals, they should 
be treated and retreated the same as persons without HIV infection, after recognizing and 
managing interactions with antiretroviral medications [100, 101].
6.1. Treatment of patients with decompensated cirrhosis
Patients with decompensated cirrhosis and those awaiting liver transplantation are managed 
according to the HCV genotype. Patients with genotypes 1 and 4 are treated with daily fixed-
dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with low initial dose of ribavirin 
(600 mg, increased as tolerated) for 12 weeks. Another regimen is a daily fixed-dose combination 
of sofosbuvir (400 mg)/velpatasvir (100 mg) with weight-based ribavirin for 12 weeks. Finally, 
daily doses of daclatasvir (60 mg) plus sofosbuvir (400 mg) with low initial dose of ribavirin (600 
mg, increased as tolerated) are given for 12 weeks. For patients who are ribavirin ineligible, the 
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recommended regime is a daily fixed dose combination of sofosbuvir (400 mg)/velpatasvir (100 
mg) for 24 weeks. Another regime is a combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 
for 24 weeks. Patients who previously failed sofosbuvir-based treatment are given a combi-
nation of ledipasvir (90 mg)/sofosbuvir (400 mg) with low initial dose of ribavirin (600 mg, 
increased as tolerated) for 24 weeks [96, 99, 102]. Patients with HCV genotype 2 or 3 infection 
and decompensated cirrhosis are treated with daily fixed-dose combination sofosbuvir (400 
mg)/velpatasvir (100 mg) with weight-based ribavirin for 12 weeks [96, 99, 102].
6.2. Patients with HCV recurrence after liver transplantation
Patients who develop HCV after transplantation and with compensated cirrhosis are treated 
with daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with weight-
based ribavirin for 12 weeks. Treatment-naïve patients with HCV genotype 1 or 4 infection 
in the allograft and with compensated liver disease and who are ribavirin ineligible can be 
treated by a daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 
weeks [96, 99, 103]. Patients with HCV genotype 1 infection in the allograft, including those 
with compensated cirrhosis can receive daily simeprevir (150 mg) plus sofosbuvir (400 mg) 
with or without weight-based ribavirin for 12 weeks. For those with early stage fibrosis, the 
recommended regimen is daily fixed-dose combination of paritaprevir (150 mg)/ritonavir 
(100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) with weight-based 
ribavirin for 24 weeks. Treatment-naïve and -experienced patients with HCV genotype 2 
infection in the allograft, including those with compensated cirrhosis, are treated with dacla-
tasvir (60 mg) plus sofosbuvir (400 mg), with low initial dose of ribavirin (600 mg, increased 
as tolerated) for 12 weeks [92, 96, 99].
7. Patients with HCV and renal impairment
In patients with mild to moderate renal impairment, no dosage adjustment is required when 
using daclatasvir (60mg), fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg), 
fixed-dose combination of sofosbuvir (400mg)/velpatasvir (100mg), or fixed-dose combination 
of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with (or without for HCV gen-
otype 4 infection) twice-daily dosed dasabuvir (250 mg), simeprevir (150 mg), or sofosbuvir 
(400 mg) to treat or retreat HCV infection in patients with appropriate genotypes [96, 99, 104].
For patients with severe renal impairment or end stage renal disease and patients with geno-
type 1a, or 1b, or 4 infection and CrCl below 30 ml/min, for whom treatment has been elected 
before kidney transplantation, the recommended daily fixed-dose combination of elbasvir 
(50 mg)/grazoprevir (100mg) for 12 weeks. Genotype 1b infection patients and CrCl below 30 
ml/min for whom the urgency to treat is high and treatment has been elected before kidney 
transplantation, daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/
ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 weeks. For patients with 
HCV genotype 2, 3, 5, or 6 infection and CrCl below 30 ml/min for whom the urgency to treat 
is high and treatment has been elected before kidney transplantation, PEG-IFN and dose-
adjusted ribavirin (200 mg daily) [104–107].
Advances in Treatment of Hepatitis C
http://dx.doi.org/10.5772/66719
35
8. Retreatment of patients who failed prior therapy [57, 96, 99, 108, 109]
Patients who failed PEG-IFN-α, ribavirin, and DAA or all DAA regimens are retreated accord-
ing to the previous therapies and genotype as follows:
 - Patients infected with HCV genotype 1 who failed after a triple combination regimen of 
PEG-IFN-α, ribavirin and telaprevir, boceprevir or simeprevir are treated with combina-
tion of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir, or sofosbuvir and daclatas-
vir, with ribavirin for 12 weeks.
 - Patients who failed on sofosbuvir alone or sofosbuvir plus ribavirin or sofosbuvir plus pe-
gylated IFN- α and ribavirin can be retreated with any of the following:
 ○ Genotypes 1, 4, 5, or 6 can be treated with sofosbuvir and ledipasvir
 ○ All genotypes can be treated with sofosbuvir and velpatasvir
 ○ Genotype 1 may be treated with ritonavir-boosted paritaprevir, ombitasvir, and 
dasabuvir
 ○ Genotype 4 is treated with ritonavir boosted, paritaprevir and ombitasvir or sofosbuvir 
plus simeprevir
 ○ Genotypes 1 or 4 are treated with grazoprevir and elbasvir for 24 weeks in F0-F2 patients 
with HCV RNA >800,000 IU/ml)
 ○ All genotypes may be treated with sofosbuvir plus daclatasvir
9. Treatment of HCV and HBV coinfection
The goal of therapy in HBV and HCV coinfection is to eradicate HCV infection and inhibit 
HBV replication. Evaluation of liver disease progression, predominance of one virus over 
another, and comorbidities are essential for optimal antiviral regimens. For patients with 
active hepatitis C, the same regimens following the same rules as for monoinfected patients 
should be applied based on AASLD and EASL recommendations [96, 99]. For patients with 
active hepatitis B before, during or after HCV clearance or with established cirrhosis, nucleo-
side or nucleotide analog (NA), tenofovir or entecavir is indicated [110, 111]. Concurrent HBV 
nucleoside/nucleotide analog therapy is indicated either if there is a potential risk of HBV 
reactivation during or after HCV clearance or if HBV replication is detectable at a significant 
level before initiation of HCV treatment [112].
Patients should be carefully investigated for the replicative status of both HBV and HCV, and 
hepatitis delta virus infection prior selecting the treatment strategy. When HCV is replicat-
ing and causes liver disease, it should be treated following the same rules as applied to HCV 
monoinfected patients. There is a potential risk of HBV reactivation during or after HCV 
clearance. Prior initiating DAA-based treatment for hepatitis C, patients should be tested 
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for HBs antigen, anti-HBc antibodies and anti-HBs antibodies. If HBs antigen is present 
or if HBV DNA is detectable in HBs antigen-negative, anti-HBc antibody-positive patients 
(“occult” hepatitis B), concurrent HBV nucleoside/nucleotide analog therapy is indicated 
[96, 99].
9.1. DAA resistance
Despite the great efficacy of the interferon-free DAA regimen, real-life experience revealed 
that approximately 5–10% of patients end up with virologic failure. Treatment failure raised 
the issue of resistance and occurrence of mutations. To date, the impact of such mutations on 
the treatment outcome is not clarified. It is not clear if the presence of mutations at baseline 
may independently lead to relapse [113]. HCV resistance-associated variants (RAVS) remain 
a challenging issue in HCV therapy. The prevalence of NS5A RAVs at baseline was shown 
to vary considerably across genotypes 1a, 1b, 3 and 4. Some studies showed that virologic 
failure tended to be more frequent when an NS5A Y93H substitution was present at base-
line. Resistance-associated substitutions (RASs) have been reported both in treatment-naïve 
patients and following treatment with protease (NS3), phosphoprotein (NS5A) and poly-
merase (NS5B) inhibitors [113].
The different next-generation sequencing (NGS) technologies for (HCV) are critical for iden-
tification of both viral genotype and resistance genetic motifs in the era of DAA therapies. A 
study [114] compared the ability of high-throughput NGS methods to generate full-length, 
deep, HCV sequence data sets and evaluated their utility for diagnostics and clinical assess-
ment. The study showed that the consensus sequences generated by different NGS methods 
were generally concordant, and majority RAVs were consistently detected. However, meth-
ods differed in their ability to detect minor populations of RAVs. NGS provided a rapid, inex-
pensive method for generating whole HCV genomes to define infecting genotypes, RAVs, 
comprehensive viral strain analysis and quasispecies diversity. Enrichment methods are par-
ticularly suited for high-throughput analysis while providing the genotype and information 
on potential DAA resistance [114].
In conclusion, discovery of short duration, safe and highly effective regimens has opened up 
new horizons for HCV cure. However, real-life experience demonstrated some challenges 
such as emergence of mutations and management of special patient populations. Despite the 
optimism for the near future and the excellent efficacy, the prohibitive cost of such regimen 
is a great obstacle that interferes with accessibility of patients in countries with high HCV 
prevalence to the new IFN-free regimens. Thus, more efforts should be made to make IFN-
free cost-effective in all clinical scenarios and accessible to all patients.
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PEG IFN peginterferon
RBV ribavirin
DAA direct-acting antiviral
GT genotype
NNI nonnucleotide polymerase inhibitor
NS5A nonstructural protein 5A
Nuc nucleotide polymerase inhibitor
PI protease inhibitor
RAV resistance-associated variant
TPV telaprevir
BOC boceprevir
RGT response-guided therapy
RdRp RNA-dependent RNA polymerase
SIM simeprevir
DNV danoprevir
EBR-GZR elbasvir-grazoprevir
SOF sofosbuvir
VEL velpatasvir
EOTR ombitasvir/paritaprevir/ritonavir + dasabuvir
GT genotype
HCV hepatitis C virus
OMV, RTV ritonavir
ART antiretroviral
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